华润医药(03320.HK)拟议成立基金从事合成生物学、创新药物及生物技术领域高增长企业投资

Group 1 - The core announcement involves China Resources Pharmaceutical (03320.HK) planning to establish a fund with an expected scale of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology [1] - The company intends to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager after its establishment [1]